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ABSTRACT
Background. Tumor budding is an independent prognos-
tic factor in colorectal cancer (CRC) and has recently been
well-defined by the International Tumour Budding Con-
sensus Conference (ITBCC).
Objective. The aim of the present study was to use the
ITBCC budding evaluation method to examine the rela-
tionship between tumor budding, tumor factors, tumor
microenvironment, and survival in patients with primary
operable CRC.
Methods. Hematoxylin and eosin-stained slides of 952
CRC patients diagnosed between 1997 and 2007 were
evaluated for tumor budding according to the ITBCC cri-
teria. The tumor microenvironment was evaluated using
tumor stroma percentage (TSP) and Klintrup–Makinen
(KM) grade to assess the tumor inflammatory cell infiltrate.
Results. High budding (n = 268, 28%) was significantly
associated with TNM stage (p\ 0.001), competent mis-
match repair (MMR; p\ 0.05), venous invasion
(p\ 0.001), weak KM grade (p\ 0.001), high TSP
(p\ 0.001), and reduced cancer-specific survival (CSS)
(hazard ratio 8.68, 95% confidence interval 6.30–11.97;
p\ 0.001). Tumor budding effectively stratifies CSS stage
T1 through to T4 (all p\ 0.05) independent of associated
factors.
Conclusions. Tumor budding effectively stratifies
patients’ survival in primary operable CRC independent of
other phenotypic features. In particular, the combination of
T stage and budding should form the basis of a new staging
system for primary operable CRC.
Tumor budding has been defined as a single tumor cell
or small cluster of four or fewer tumor cells at the invasive
front12,18 and should be considered a promising and strong
prognostic factor in colorectal cancer (CRC).19 Widespread
reporting of tumor budding has not progressed to routine
clinical practice due to a lack of consensus on scoring
methods. However, routine reporting is now advocated by
using the approach outlined by the International Tumour
Budding Consensus Conference (ITBCC), with recom-
mendations for the assessment and reporting of tumor
budding in CRC.6
The ITBCC recommends that tumor budding should be
included in future CRC guidelines and protocols and
should be considered, along with other clinicopathological
factors, in a multidisciplinary setting. The recent dataset for
histopathological reporting of CRC by the royal pathologist
stated that they would reconsider reporting tumor budding
when new data become available.4
The tumor microenvironment also plays an important
role in CRC outcomes. Marked peritumoral inflammation
has been associated with favorable outcome,3,14 while the
presence of a high tumor stroma percentage (TSP) has been
validated as a stage-independent marker of reduced sur-
vival in patients with primary operable CRC.7,8. Both
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contribute to the development of a tumor microenviron-
ment score that can potentially supplement the current
TNM staging system.9
The aim of this study was to assess the proposed method
by ITBCC in clinical practice and investigate the rela-
tionship between tumor budding and tumor factors, tumor
microenvironment, and survival in primary operable CRC.
PATIENTS AND METHODS
Patients
Patients were identified from a prospectively collected
database of patients undergoing surgery for CRC between
1997 and 2007 at the Royal Infirmary, Western Infirmary
and Stobhill Hospital, Glasgow. Any patient with a syn-
chronous cancer, inflammatory bowel disease, and
mortality within 30 days of surgery, who had received
neoadjuvant therapy, was excluded. Furthermore, patients
who had their disease managed entirely endoscopically,
without formal colonic or rectal resection, were also
excluded from the study.
Patients were staged according to the TNM criteria that
was applicable at the time of surgery and to current prac-
tice in the UK.4 The West of Scotland Research Ethics
Committee granted study approval. Patients were followed
up for at least 5 years, and the date and cause of death were
cross-checked with electronic case records. Cancer-specific
survival (CSS) was measured from the date of surgery until
the date of death from CRC.
Routine Stains: Hematoxylin and Eosin and Elastica
For evaluation, two consecutive cut samples from each
specimen were stained; one was routinely stained with
hematoxylin and eosin (H&E), and the other was stained
with Miller’s elastic stain (BDH, Poole, Dorset, UK) and
counterstained with H&E. Routine pathological elastica
staining was used to assess the presence of venous inva-
sion.13. Only venous invasion was evaluated and no special
staining was utilized to improve the assessment of lym-
phatic or perineural invasion.
Assessment of Tumor Budding
Tumor budding has been assessed on scanned H&E-
stained slides in a single hotspot as defined by ITBCC.
Tumor budding was counted on H&E slides, and was
assessed in one hotspot (in a field measuring 0.785 mm2) at
the invasive front. A two-tier system was used along with
the budding count to facilitate risk stratification in CRC.
FIG. 1 Example of a high tumor budding, b high inflammatory infiltrate (Klintrup–Makinen grade 4), and c high tumor stroma percentage
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Cut-offs used were: low, 0–9 buds; and high, C 10 buds
(Fig. 1a).
Tumor budding was evaluated by two different obser-
vers to ensure reliability, and co-scoring of randomly
selected cases was carried out by HvW and PA. The
interobserver intraclass correlation coefficient (ICCC) for
the scores was 0.794 (p\ 0.001).
Evaluation of Tumor Inflammatory Cell Infiltrate
and Tumor Stroma Percentage
Klintrup–Makinen grade was used to assess the gener-
alized inflammatory infiltrate semi-quantitatively. Full
H&E sections of the deepest point of tumor invasion were
used, whereby inflammatory cell density at the invasive
margin was graded using a 4-point scale; it was classified
as low-grade (no increase or mild/patchy increase in
inflammatory cells) or high-grade (prominent inflammatory
reaction forming a band at the invasive margin, or florid
cup-like infiltrate at the invasive edge with destruction of
cancer cell islands), as previously described3,14 (Fig. 1b).
Tumor stroma percentage was assessed semi-quantita-
tively using full sections of the deepest point of tumor
invasion; the proportion of stroma was calculated as a
percentage of the visible field, excluding areas of mucin
deposition or necrosis. Tumors were subsequently graded
as low (50%) or high ([ 50%) TSP as previously descri-
bed8 (Fig. 1c).
Assessment of Ki-67, Mismatch Repair (MMR)
and BRAF Status
The Ki-67 proliferation index was assessed cohort using
a threshold of 50%. A subset of patients in the full cohort
underwent evaluation of the mismatch repair (MMR) and
BRAF statuses. Using immunohistochemistry, a previously
constructed tissue microarray comprising cores of forma-
lin-fixed paraffin-embedded cancer tissue was used to
assess MMR and BRAF status. Immunohistochemistry for
MMR status has been previously described.10 MMR
TABLE 1 Clinicopathological features of patients with primary
operable colorectal cancer and cancer-specific survival
N (%)
[952 patients]
Univariate analysis
[CSS]
p value
Host characteristics
Age (years) 1.00 (0.76–1.32) 0.984
\ 65 297 (31)
[ 65 655 (69)
Sex 1.20 (0.92–1.56) 0.176
Female 456 (48)
Male 496 (52)
Adjuvant therapy 1.03 (0.68–1.28) 0.859
Yes 105 (34)
No 204 (64)
Tumor characteristics
Tumor site 1.18 (0.89–1.58) 0.247
Colon 713 (75)
Rectum 239 (25)
Tstage 1.97 (1.61–2.41) \ 0.001
1 40 (4)
2 117 (12)
3 514 (54)
4 281 (30)
N stage 2.09 (1.78–2.47) \ 0.001
0 582 (61)
1 253 (27)
2 113 (12)
TNM stage 2.95 (2.38–3.66) \ 0.001
1 131 (14)
2 445 (47)
3 355 (37)
4 21 (2)
Ki-67 proliferation index 0.60 (0.46–0.79) \ 0.001
Low 450 (48)
High 491 (52)
Mismatch repair status 0.64 (0.50–0.82) 0.001
Competent 763 (83)
Deficient 162 (17)
BRAF status 0.91 (0.65–1.28) 0.589
Low 735 (80)
High 187 (20)
Tumor necrosis 1.08 (0.82–1.41) 0.579
Low 581 (62)
High 362 (38)
Venous invasion 2.62 (2.02–3.41) \ 0.001
Absent 631 (66)
Present 321 (34)
Klintrup–Makinen grade 0.33 (0.23–0.46) \0.001
Weak 651 (69)
Strong 296 (31)
TABLE 1 continued
N (%)
[952 patients]
Univariate analysis
[CSS]
p value
Tumor stroma percentage 2.07 (1.58–2.74) \ 0.001
Low 704 (75)
High 232 (25)
Tumor budding 10.41 (7.76–13.96) \ 0.001
Low 684 (72)
High 268 (28)
CSS cancer-specific survival
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protein expression was reported as MMR-competent or -
deficient, by a single blinded observer. The assessment of
BRAF status was performed as previously described by our
group11 and therefore the results were incorporated in our
study. BRAF V600E mutation was reported as absent or
present by a single blinded observer.
Statistical Analysis
Interrelationships between tumor location, clinico-
pathological characteristics, and measures of the tumor
microenvironment were analyzed using the Chi square test.
Five-year CSS and overall survial was examined using
Kaplan–Meier log-rank survival analysis and univariate
Cox proportional hazards regression to calculate hazard
ratios and 95% confidence intervals. Variables found to be
statistically significant (p\ 0.05) on univariate analysis
were entered into a Cox regression multivariate model
using a backward conditional method. A p value\ 0.05
was significant. Analyses were performed using SPSS
software version 24 (IBM SPSS, Armonk, NY, USA).
RESULTS
The cohort consisted of 952 patients. Clinical and
pathological features are shown in Table 1. Two-thirds of
patients included were over the age of 65 years, and 52%
were male. Overall, 131 (14%) patients had TNM stage I
disease, 445 (47%) had stage II disease, 355 (37%) had
stage III disease, and 21 (2%) had stage IV disease; 713
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FIG. 2 Relationship between low- and high-grade tumor budding
and cancer-specific survival in patients with primary operable
colorectal cancer (p\ 0.001). TB tumor budding
TABLE 2 The relationship between tumor budding and
clinicopathological features of patients with primary operable
colorectal cancer
Tumor budding [N (%)] p value
Low [684 (72%)] High [268 (28%)]
Host characteristics
Age (years) 0.110
\ 65 205 (30) 92 (34)
[ 65 479 (70) 176 (66)
Sex 0.199
Male 334 (49) 122 (46)
Female 350 (51) 146 (54)
Tumor characteristics
Tumor site 0.451
Colon 511 (75) 202 (75)
Rectum 173 (25) 66 (25)
T stage \ 0.001
I 38 (6) 2 (1)
II 101 (15) 16 (6)
III 393 (57) 121 (45)
IV 152 (22) 129 (48)
N stage \ 0.001
0 471 (69) 111 (42)
1 154 (23) 99 (37)
2 55 (8) 57 (21)
TNM stage \ 0.001
1 120 (17) 11 (4)
2 349 (51) 96 (36)
3 209 (31) 146 (55)
4 6 (1) 15 (5)
Proliferation index 0.285
Low 318 (47) 131 (49)
High 357 (53) 134 (51)
Mismatch repair status 0.012
Competent 539 (81) 224 (87)
Deficient 129 (19) 33 (13)
BRAF status 0.066
Low 519 (78) 216 (83)
High 143 (22) 44 (17)
Necrosis 0.499
\ 25% 417 (62) 164 (61)
[ 25% 259 (38) 103 (39)
Venous invasion \ 0.001
Absent 493 (72) 138 (52)
Present 191 (28) 130 (48)
Klintrup–Makinen \ 0.001
Weak 432 (64) 219 (82)
strong 248 (36) 48 (18)
Tumor stroma percentage \ 0.001
B 50 542 (81) 162 (61)
[ 50 127 (19) 105 (39)
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(75%) patients had colon tumors and 239 (25%) had rectal
cancer. Venous invasion was present in 321 (34%) tumors,
and tumor necrosis was present in 362 (38%) tumors. High-
grade tumor budding was present in 28% of tumors, a low-
grade inflammatory cell infiltrate was present in 69% of
tumors, and 25% of tumors had a high TSP. MMR
deficiency was identified in 17% of patients, and 20% of
patients had BRAF V600E mutations. The median follow-
up for patients was 11.7 years (range 6.4–16.3), with 226
cancer deaths and 271 non-cancer deaths. On univariate
survival analysis, T stage (p\ 0.001), N stage (p\ 0.001),
TNM stage (p\ 0.001), Ki-67 proliferation index
TABLE 3 Relationship between T stage, clinicopathological characteristics, and cancer-specific survival in patients with primary operable
colorectal cancer
T stage Univariate analysis p value Multivariate analysis p value
T1 [n = 40]
N stage (0/1/2) 1.55 (0.16–14.92) 0.704
Ki67 proliferation Index (low/high) 1.66 (0.17–15.98) 0.660
Mismatch repair status (competent/deficient) 1.44 (0.14–13.85) 0.753
BRAF status (low/high) 0.04 (0–308.53) 0.569
Tumor necrosis (low/high) 0.31 (0.00–375.83) 0.468
Venous invasion (no/yes) 0.46 (0.0–17,931) 0.760
Klintrup–Makinen grade (weak/strong) 0.142 (0.015–1.37) 0.091 0.97 (0.008–1.19) 0.068
Tumor stroma percentage (low/high) 0.043 (0.00–17,062) 0.685
Tumor budding (low/high) 8.99 (0.92–88.13) 0.059 8.44 (1.12–303.95) 0.042
T2 [n = 117]
N stage (0/1/2) 1.92 (0.88–4.20) 0.104
Ki67 proliferation index (low/high) 0.557 (0.26–2.02) 0.547
Mismatch repair status (competent/deficient) 0.75 (0.17–3.33) 0.704
BRAF status (low/high) 1.21 (0.34–4.33) 0.78
Tumor necrosis (low/high) 1.41 (0.48–4.13) 0.530
Venous invasion (no/yes) 3.18 (1.12–9.02) 0.030 2.78 (0.96–8.11) 0.060
Klintrup–Makinen grade (weak/strong) 0.60 (0.22–1.66) 0.328
Tumor stroma percentage (low/high) 1.41 (0.48–4.13) 0.530
Tumor budding (low/high) 8.39 (3.03.03–23.20) \ 0.001 7.86 (2.81–21.95) \ 0.001
T3 [n = 514]
N stage (0/1/2) 1.74 (1.36–2.22) \ 0.001 1.20 (0.92–1.56) 0.176
Ki67 proliferation index (low/high) 0.98 (0.97–0.99) 0.002 0.57 (0.38–0.87) 0.008
Mismatch repair status (competent/deficient) 0.87 (0.50–1.50) 0.610
BRAF status (low/high) 0.96 (0.60–1.56) 0.882
Tumor necrosis (low/high) 1.04 (0.70–1.54) 0.848
Venous invasion (no/yes) 1.78 (1.21–2.62) 0.003 1.74 (1.16–2.60) 0.007
Klintrup–Makinen grade (weak/strong) 0.37 (0.21–0.65) 0.001 0.55 (0.30–0.99) 0.049
Tumor stroma percentage (low/high) 1.75 (1.15–2.66) 0.008 0.96 (0.61–1.53) 0.877
Tumor budding (low/high) 8.98 (4.03–9.39) \ 0.001 9.11 (5.92–14.03) \ 0.001
T4 [n = 281]
N stage (0/1/2) 2.07 (1.62–2.65) \ 0.001 1.34 (1.02–1.76) 0.032
Ki67 proliferation index (low/high) 0.78 (0.57–1.18) 0.246
Mismatch repair status (competent/deficient) 0.21 (0.84–0.51 0.001 0.32 (0.13–0.80) 0.015
BRAF status (low/high) 0.84 (0.49–1.41) 0.504
Tumor necrosis (low/high) 0.93 (0.63–1.39) 0.736
Venous invasion (no/yes) 2.99 (1.98–4.52) \ 0.001 1.89 (1.22–2.95) 0.005
Klintrup–Makinen grade (weak/strong) 0.35 (0.19–0.63) \0.001 0.62 (0.33–1.14) 0.124
Tumor stroma percentage (low/high) 0.99 (0.98–1.01) 0.505
Tumor budding (low/high) 10.36 (5.96–18.01) \ 0.001 8.23 (4.59–14.73) \ 0.001
Relationship Between Tumor Budding, Tumor Microenvironment, and Survival in CRC
(p\ 0.001), MMR (p B 0.001), venous invasion
(p\ 0.001), Klintrup–Makinen (KM) grade (p\ 0.001),
TSP (p\ 0.001), and tumor budding (p\ 0.001) (Fig. 2)
were significantly associated with CSS.
The relationship between tumor budding, clinicopatho-
logical features of primary operable CRC, and tumor
budding are shown in Table 2. High-grade budding was
associated with T stage (p\ 0.001), N stage (p\ 0.001),
TNM stage (p\ 0.001), MMR status (p\ 0.05), venous
invasion (p\ 0.001), KM grade (p\ 0.001), and TSP
(p\ 0.001).
The relationship between T stage (1–4), clinicopatho-
logical characteristics, and CSS in patients with primary
operable CRC are shown in Table 3 and Fig. 3a–d. T1 and
T2 stages were associated with tumor budding (p\ 0.01
and p\ 0.001, respectively), and T3 stage was associated
with venous invasion (p\ 0.01), Ki-69 proliferation index
(p\ 0.01), KM grade (p\ 0.05), and tumor budding
(p\ 0.001). T4 stage was associated with N stage
(p\ 0.05), venous invasion (p\ 0.05), MMR status
(p\ 0.05), and tumor budding (p\ 0.001).
The relationship between TNM stage, clinicopathologi-
cal characteristics, and CSS in patients with primary
operable CRC are shown in Table 4. TNM stages I and II
were associated with venous invasion (p\ 0.05), KM
grade (p\ 0.05), and tumor budding (p\ 0.001). TNM
stage III was associated with venous invasion (p\ 0.05)
and tumor budding (p\ 0.001), and TNM stage IV was
associated with tumor budding (p\ 0.05).
Tumor budding is an independent prognostic factor in
all stages with venous invasion, independent of stages I–III,
and KM grade, independent of stages I–II.
DISCUSSION
The results of the present study show that tumor budding
effectively stratifies CSS in patients with primary operable
cancer. Furthermore, compared with other tumor charac-
teristics, including T and nodal stage, tumor budding had
the highest hazard ratio, approximately three times that of
any other tumor characteristic. Therefore, tumor budding is
a good candidate to form the basis of a new staging system
for primary operable CRC.
It was also of interest that in T1 and T2 tumors, only
tumor budding had significant prognostic value. This
would indicate that tumor budding occurs early in tumor
invasion and may represent aggressive characteristics of
malignant tumors, such as loss of cell adhesion and local
invasion.5,20 Indeed, it may be argued that given its asso-
ciation with other characteristics of the tumor and its
microenvironment, tumor budding is the most important
component of tumor invasion. Indeed, the prognostic
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FIG. 3 Relationship between tumor budding and cancer-specific survival in a T stage 1, b T stage 2, c T stage 3, and d T stage 4 primary
operable colorectal cancer (p\ 0.05). Cum cumulative
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importance of tumor budding in local excision specimens
in predicting outcome and/or predictive of nodal metastatic
disease in stage pT1 CRCs is increasingly being
recognized.1,16,17,20
The Ki-67 antigen is widely used to evaluate tumor
proliferative activity as autonomous cell proliferation is a
main feature of neoplasia. However, despite the clear
association of tumor budding with migration and invasion,
paradoxically, tumor buds appear not to be associated with
proliferation. However, the association between tumor
budding intensity and proliferative activity is still poorly
understood and it is speculated that host invasion, by
budding tumor cells, might be activated only after the cell
cycle has been switched off.2,15 Further work is required to
elucidate the molecular basis of this relationship.
In the present study, it was of interest that other com-
ponents of the tumor microenvironment had increasing
prognostic value in patients with T3 and T4 disease. The
basis of this observation is not clear, however it may be
that in larger, more invasive tumors, the components of the
tumor microenvironment, such as the tumor stroma and
inflammatory infiltrate, become more important in
TABLE 4 Relationship between TNM stage, clinicopathological characteristics, and cancer-specific survival in patients with primary operable
colorectal cancer
TNM stage Univariate analysis p value Multivariate analysis p value
Stage 1 [n = 131]
Ki67 proliferation index (low/high) 0.65 (0.22–1.95) 0.445
Mismatch repair status (competent/deficient) 0.39 (0.0–21.82) 0.313
BRAF status (low/high) 0.57 (0.07–4.38) 0.585
Tumor necrosis (low/high) 1.69 (0.57–5.19) 0.353
Venous invasion (absent/present) 3.44 (1.05–11.22) 0.041 3.53 (1.02–12.17) 0.046
Klintrup–Makinen grade (weak/strong) 0.28 (0.08–0.89) 0.032 0.27 (0.08–0.94) 0.040
Tumor stroma percentage (low/high) 1.79 (0.49–6.50) 0.378
Tumor budding (low/high) 9.96 (3.34–29.72) \ 0.001 7.90 (2.63–23.74) \ 0.001
Stage 2 [n = 445]
Ki67 proliferation index (low/high) 0.55 (0.34–0.89) 0.014
Mismatch repair status (competent/deficient) 0.58 (0.29–1.14) 0.113
BRAF status (low/high) 0.97 (0.55–1.73) 0.927
Tumor necrosis (low/high) 0.87 (0.53–1.40) 0.555
Venous invasion (absent/present) 2.34 (1.47–3.74) 0.001 2.05 (1.27–3.31) 0.003
Klintrup–Makinen grade (weak/strong) 0.41 (0.22–0.77) 0.005 0.51 (0.26–0.97) 0.040
Tumor stroma percentage (low/high) 3.07 (1.89–4.98) 0.001 1.53 (0.92–2.54) 0.102
Tumor budding (low/high) 10.21 (6.26–16.64) \ 0.001 10.23 (6.12–17.07) \ 0.001
Stage 3 [n = 355]
Ki67 proliferation index (low/high) 0.66 (0.46–0.95) 0.025 0.99 (0.99–1.00) 0.296
Mismatch repair status (competent/deficient) 0.83 (0.45–1.50) 0.529
BRAF status (low/high) 0.83 (0.52–1.34) 0.453
Tumor necrosis (low/high) 1.29 (0.90–1.85) 0.166
Venous invasion (absent/present) 1.81 (1.27–2.59) 0.001 1.55 (1.08–2.23) 0.017
Klintrup–Makinen grade (weak/strong) 0.46 (0.28–0.75) 0.0502 0.62 (0.38–1.01) 0.054
Tumor stroma percentage (low/high) 1.27 (0.87–1.85) 0.218
Tumor budding (low/high) 7.46 (4.87–11.42) \ 0.001 9.11 (5.92–14.03) \ 0.001
Stage 4 [n = 21]
Ki67 proliferation index (low/high) 0.58 (0.21–1.61) 0.294
Mismatch repair status (competent/deficient) 4.27 (0.48–38.24) 0.195
BRAF status (low/high) 0.72 (0.23–2.21) 0.561
Tumor necrosis (low/high) 0.63 (0.18–2.23) 0.478
venous invasion (absent/present) 1.28 (0.47–3.47) 0.628
Klintrup–Makinen grade (weak/strong) 0.31 (0.0–13.67) 0.264
Tumor stroma percentage (low/high) 1.48 (0.55–3.99) 0.444
Tumor budding (low/high) 10.82 (1.38–85.02) 0.024 10.82 (1.38–85.02) 0.024
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determining the future of the primary tumor. For example,
the good outcome associated with a pronounced tumor
inflammatory cell infiltrate may be due to the effective
elimination of the tumor. In contrast, the poor outcome
associated with the pronounced tumor stroma may be due
to the supportive environment for the tumor. Indeed, Ueno
et al. reported an association between fibrotic immature
stroma and the intensity of tumor budding as histological
dedifferentiation, including dissociation of cancer cells and
the first step of invasion. Therefore, the present findings
further support a pertinent role of tumor stroma in facili-
tating tumor cell de-differentiation and dissemination.
Further work is required to elucidate the molecular basis of
this relationship.
CONCLUSIONS
The findings of the present study indicate that tumor
budding effectively stratifies cancer survival in patients
with primary operable CRC. This stratification is inde-
pendent of recognized tumor factors, including TNM stage.
Therefore, the ITBCC budding evaluation method should
be used to assess tumor budding and may form the basis of
a new staging system in patients with CRC.
OPEN ACCESS This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://crea
tivecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
REFERENCES
1. Brown IS, Bettington ML, Bettington A, Miller G, Rosty C.
Adverse histological features in malignant colorectal polyps: a
contemporary series of 239 cases. J Clin Pathol. 2016;69:292–9.
2. Dawson H, Koelzer VH, Karamitopoulou E, et al. The apoptotic
and proliferation rate of tumour budding cells in colorectal cancer
outlines a heterogeneous population of cells with various impacts
on clinical outcome. Histopathology. 2014;64:577–84.
3. Klintrup K, Ma¨kinen JM, Kauppila S, et al. Inflammation and
prognosis in colorectal cancer. Eur. J. Cancer. 2005;41:2645–54.
4. Loughrey M, Quirke P, Shepherd NA. Standards and datasets for
reporting cancers. Dataset for histopathological reporting of
colorectal cancer. Sep 2018. https://www.rcpath.org/uploads/asse
ts/uploaded/0d5e22ce-be66-474c-ba3097adae84121d. Assessed
23 Feb 2019.
5. Lugli A, Karamitopoulou E, Panayiotides I, et al. CD8? lym-
phocytes/tumour-budding index: an independent prognostic
factor representing a ‘pro-/anti-tumour ‘approach to tumour host
interaction in colorectal cancer. Br J Cancer. 2009;101:1382.
6. Lugli A, Kirsch R, Ajioka Y, et al. Recommendations for
reporting tumor budding in colorectal cancer based on the
International Tumor Budding Consensus Conference (ITBCC)
2016. Mod Pathol. 2017;30:1299.
7. Mesker WE, Junggeburt J, Szuhai K, et al. The carcinoma–stro-
mal ratio of colon carcinoma is an independent factor for survival
compared to lymph node status and tumor stage. Anal. Cell.
Pathol. 2007;29:387–98.
8. Park J, Richards C, McMillan D, Horgan P, Roxburgh C. The
relationship between tumour stroma percentage, the tumour
microenvironment and survival in patients with primary operable
colorectal cancer. Ann. Oncol. 2014;25:644–51.
9. Park JH, McMillan DC, Powell AG, et al. Evaluation of a tumor
microenvironment-based prognostic score in primary operable
colorectal cancer. Clin. Cancer Res. 2015;21:882–8.
10. Park JH, Powell AG, Roxburgh CS, Horgan PG, McMillan DC,
Edwards J. Mismatch repair status in patients with primary
operable colorectal cancer: associations with the local and sys-
temic tumour environment. Br J Cancer. 2016;114:562.
11. Patel M, McSorley ST, Park JH, et al. The relationship between
right-sided tumour location, tumour microenvironment, systemic
inflammation, adjuvant therapy and survival in patients under-
going surgery for colon and rectal cancer. Br J Cancer.
2018;118:705.
12. Prall F, Nizze H, Barten M. Tumour budding as prognostic factor
in stage I/II colorectal carcinoma. Histopathology.
2005;47:17–24.
13. Roxburgh CS, McMillan DC, Anderson JH, McKee RF, Horgan
PG, Foulis AK. Elastica staining for venous invasion results in
superior prediction of cancer-specific survival in colorectal can-
cer. Ann. Surg. 2010;252:989–97.
14. Roxburgh CS, Salmond JM, Horgan PG, Oien KA, McMillan
DC. Tumour inflammatory infiltrate predicts survival following
curative resection for node-negative colorectal cancer. Eur J
Cancer. 2009;45:2138–45.
15. Rubio CA. Arrest of cell proliferation in budding tumor cells
ahead of the invading edge of colonic carcinomas. A preliminary
report. Anticancer Res. 2008;28:2417–20.
16. Ueno H, Jones AM, Wilkinson KH, Jass J, Talbot I. Histological
categorisation of fibrotic cancer stroma in advanced rectal cancer.
Gut. 2004;53:581–6.
17. Ueno H, Mochizuki H, Hashiguchi Y, et al. Risk factors for an
adverse outcome in early invasive colorectal carcinoma. Gas-
troenterology. 2004;127:385–94.
18. Ueno H, Murphy J, Jass J, Mochizuki H, Talbot I. Tumourbud-
ding’as an index to estimate the potential of aggressiveness in
rectal cancer. Histopathology. 2002;40:127–32.
19. van Wyk HC, Park JH, Edwards J, Horgan PG, McMillan DC,
Going JJ. The relationship between tumour budding, the tumour
microenvironment and survival in patients with primary operable
colorectal cancer. British J Cancer. 2016;115:156.
20. Wang H-S, Liang W-Y, Lin T-C, et al. Curative resection of T1
colorectal carcinoma: risk of lymph node metastasis and long-
term prognosis. Dis Colon Rectum. 2005;48:1182–92.
Publisher’s Note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
H. C. van Wyk et al.
